News Headlines Article

FDA approves new Hep C drug combination, price unknown for now
Modern Healthcare

The Food and Drug Administration on Friday approved Viekira Pak, a combination of pills that becomes the fourth treatment the agency has approved to treat hepatitis C. Viekira Pak, produced by North Chicago-based AbbVie, includes ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets. It will compete with three other hep C drugs: Johnson & Johnson’s Olysio and Gilead Sciences’ Sovaldi and Harvoni.Treatment for HCV, a liver disease that can cause cirrhosis or liver cancer, is extremely expensive.